JP2020521784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521784A5 JP2020521784A5 JP2019565921A JP2019565921A JP2020521784A5 JP 2020521784 A5 JP2020521784 A5 JP 2020521784A5 JP 2019565921 A JP2019565921 A JP 2019565921A JP 2019565921 A JP2019565921 A JP 2019565921A JP 2020521784 A5 JP2020521784 A5 JP 2020521784A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- group
- orn
- functional variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims 53
- 238000006467 substitution reaction Methods 0.000 claims 31
- 235000014113 dietary fatty acids Nutrition 0.000 claims 28
- 229930195729 fatty acid Natural products 0.000 claims 28
- 239000000194 fatty acid Substances 0.000 claims 28
- 150000004665 fatty acids Chemical class 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 125000000539 amino acid group Chemical group 0.000 claims 23
- 150000001413 amino acids Chemical class 0.000 claims 13
- 244000137850 Marrubium vulgare Species 0.000 claims 12
- 125000003277 amino group Chemical group 0.000 claims 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 5
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010016626 Dipeptides Proteins 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- -1 with L Chemical class 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- RIFRYROLBMMDGQ-UHFFFAOYSA-N 5-amino-2-(2-aminoethyl)-3-oxohexanoic acid Chemical compound NC(CC(=O)C(C(=O)O)CCN)C RIFRYROLBMMDGQ-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 claims 1
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004129 fatty acid metabolism Effects 0.000 claims 1
- 230000004136 fatty acid synthesis Effects 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 230000004190 glucose uptake Effects 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 108010015792 glycyllysine Proteins 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 230000002473 insulinotropic effect Effects 0.000 claims 1
- 235000020825 overweight Nutrition 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 108010002139 very low density lipoprotein triglyceride Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173628 | 2017-05-31 | ||
| EP17173628.3 | 2017-05-31 | ||
| PCT/EP2018/064355 WO2018220123A1 (en) | 2017-05-31 | 2018-05-31 | Long-acting gip peptide analogues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521784A JP2020521784A (ja) | 2020-07-27 |
| JP2020521784A5 true JP2020521784A5 (cg-RX-API-DMAC7.html) | 2021-07-26 |
Family
ID=59021262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565921A Pending JP2020521784A (ja) | 2017-05-31 | 2018-05-31 | 長時間作用性ｇｉｐペプチド類似体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11572399B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3630806B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020521784A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102743887B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110691788B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018276434B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019025195A8 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2972848T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3630806T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018220123A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2685987T3 (es) | 2014-09-05 | 2018-10-15 | University Of Copenhagen | Análogos de péptidos gip |
| BR112019025195A8 (pt) | 2017-05-31 | 2020-07-07 | Univ Copenhagen | análogos do peptídeo gip de ação prolongada |
| CA3097939A1 (en) | 2018-05-04 | 2019-11-07 | Novo Nordisk A/S | Gip derivatives and uses thereof |
| US12187773B2 (en) * | 2018-12-03 | 2025-01-07 | Antag Therapeutics Aps | Modified GIP peptide analogues |
| WO2023139106A2 (en) | 2022-01-18 | 2023-07-27 | Novo Nordisk A/S | Long-acting gipr antagonists |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| BR9906857A (pt) | 1998-01-30 | 2000-11-14 | Novo Nordisk As | Seringas de injeção |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| DE69918070T2 (de) | 1998-03-13 | 2005-08-25 | Novo Nordisk A/S | Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien |
| EP1119625B1 (en) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| PL202367B1 (pl) | 1998-12-07 | 2009-06-30 | Sod Conseils Rech Applic | Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków |
| US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| GB0404124D0 (en) * | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| ATE406384T1 (de) | 2000-12-07 | 2008-09-15 | Lilly Co Eli | Glp-1 fusion proteine |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| BRPI0606992A2 (pt) | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| JP5412273B2 (ja) | 2006-03-21 | 2014-02-12 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | ペプチド−ぺプチダーゼ阻害剤及びその使用 |
| AU2007284365A1 (en) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| WO2010016936A1 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide |
| PL2320923T3 (pl) | 2008-08-07 | 2015-06-30 | Ipsen Pharma Sas | Skrócone analogi peptydu insulinotropowego zależnego od glukozy |
| CA2732973A1 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Glucose-dependent insulinotropic polypeptide analogues |
| CN102171244B (zh) | 2008-08-07 | 2015-05-13 | 益普生制药股份有限公司 | 糖依赖性胰岛素释放肽的类似物 |
| US8999940B2 (en) | 2008-08-07 | 2015-04-07 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
| US8551946B2 (en) * | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| KR20140020851A (ko) * | 2010-12-22 | 2014-02-19 | 마르카디아 바이오테크, 인코퍼레이트 | Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법 |
| EP2717925A1 (en) * | 2011-06-10 | 2014-04-16 | Universität Bern | Imaging and treatment of neuroendocrine tumors with glucose - dependent insulinotropic polypeptide or analogues or antagonists thereof |
| JP5914641B2 (ja) * | 2011-06-10 | 2016-05-11 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用 |
| EP2986314A4 (en) | 2013-03-15 | 2016-04-13 | Univ Indiana Res & Tech Corp | PRODRUGS WITH EXTENDED EFFECT |
| ES2685987T3 (es) * | 2014-09-05 | 2018-10-15 | University Of Copenhagen | Análogos de péptidos gip |
| AU2015340586B2 (en) * | 2014-10-29 | 2020-04-30 | Zealand Pharma A/S | GIP agonist compounds and methods |
| EP3310376A4 (en) | 2015-06-17 | 2019-01-23 | The California Institute for Biomedical Research | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF |
| WO2018069442A1 (en) * | 2016-10-12 | 2018-04-19 | University Of Copenhagen | Peptide dual agonists of gipr and glp2r |
| EP3560515B1 (en) | 2016-12-26 | 2023-11-15 | Kao Corporation | Gip inhibitors for use in improving motor control function |
| EP3569248B1 (en) | 2016-12-26 | 2023-12-06 | Kao Corporation | Gip inhibitors for improving cognitive function |
| JP7158142B2 (ja) | 2016-12-26 | 2022-10-21 | 花王株式会社 | 低体温改善剤 |
| BR112019025195A8 (pt) | 2017-05-31 | 2020-07-07 | Univ Copenhagen | análogos do peptídeo gip de ação prolongada |
-
2018
- 2018-05-31 BR BR112019025195A patent/BR112019025195A8/pt unknown
- 2018-05-31 PL PL18728872.5T patent/PL3630806T3/pl unknown
- 2018-05-31 ES ES18728872T patent/ES2972848T3/es active Active
- 2018-05-31 EP EP18728872.5A patent/EP3630806B1/en active Active
- 2018-05-31 EP EP24150677.3A patent/EP4361173A3/en active Pending
- 2018-05-31 WO PCT/EP2018/064355 patent/WO2018220123A1/en not_active Ceased
- 2018-05-31 CN CN201880036341.0A patent/CN110691788B/zh active Active
- 2018-05-31 JP JP2019565921A patent/JP2020521784A/ja active Pending
- 2018-05-31 US US16/617,698 patent/US11572399B2/en active Active
- 2018-05-31 AU AU2018276434A patent/AU2018276434B2/en active Active
- 2018-05-31 KR KR1020197034279A patent/KR102743887B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521784A5 (cg-RX-API-DMAC7.html) | ||
| JP7605747B2 (ja) | 修飾されたｇｉｐペプチド類似体 | |
| JP7658877B2 (ja) | インクレチン類似体およびその使用 | |
| KR102440323B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| JP6017754B2 (ja) | グルカゴン／ｇｌｐ−１受容体コアゴニスト | |
| JP5986550B2 (ja) | Ｎ末端において修飾されたグルコース依存性インスリン分泌刺激ポリペプチド（ｇｉｐ）のアナログ | |
| RU2485135C2 (ru) | Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) | |
| DK2320923T3 (en) | Truncated analogues of glucose-dependent insulinotropic polypeptide | |
| JP2013518115A5 (cg-RX-API-DMAC7.html) | ||
| JP2011524420A5 (cg-RX-API-DMAC7.html) | ||
| KR20150131213A (ko) | 인슐린-인크레틴 접합체들 | |
| HUE028072T2 (en) | GIP-based agonists for the treatment of metabolic disease and obesity | |
| KR20120123443A (ko) | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 | |
| US20180280480A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| EP2036923A1 (en) | Improved derivates of amylin | |
| JP2013510829A (ja) | 長時間作用型ｙ２受容体アゴニスト | |
| JP2007001987A5 (cg-RX-API-DMAC7.html) | ||
| JP2013505221A (ja) | 長時間作用性ｙ２受容体アゴニスト | |
| JP2016512213A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020115048A5 (cg-RX-API-DMAC7.html) | ||
| CN110691788B (zh) | 长效gip肽类似物 | |
| RU2752787C1 (ru) | Пептидный аналог ацилированного оксинтомодулина | |
| JP2007536214A (ja) | Ｇｌｐ−１類似体 | |
| JPWO2021110845A5 (cg-RX-API-DMAC7.html) | ||
| KR102906485B1 (ko) | 변형된 gip 펩티드 유사체 |